The Lipid Panel Was Fine. The Patient Was Not: A Case in Advanced Cardiovascular Risk Assessment

Cardiovascular disease remains the leading cause of death in women, yet the tools most commonly used to assess risk in clinical practice were largely derived from male populations and male disease patterns. For postmenopausal women specifically, the conventional lipid panel frequently underestimates true cardiovascular risk — not because cholesterol does not matter, but because the panel as ordered does not capture the markers that matter most in this population. This case illustrates what a comprehensive functional cardiovascular workup looks like, how estrogen loss reshapes the metabolic and vascular environment, and how layering advanced biomarkers with physiologic phenotyping and imaging produces a clinical picture that is both more accurate and more actionable.

The Patient

A 54-year-old postmenopausal woman was referred for a second opinion following an annual wellness visit in which her primary care physician noted “borderline cholesterol” and recommended dietary changes and a return visit in six months. Her standard lipid panel showed:

By standard interpretation, this was a borderline panel warranting lifestyle counseling. The patient, however, had a strong family history of premature coronary artery disease: her father had a myocardial infarction at 57, and her older brother had undergone coronary stenting at 52. She had entered menopause at 51 after a surgical oophorectomy for benign disease and had not been offered hormone therapy. Her chief complaints were fatigue, brain fog, disrupted sleep, and progressive weight gain — eleven pounds in the three years since her oophorectomy despite no meaningful change in diet or activity. She was a non-smoker with no history of hypertension or diabetes.

What the Standard Panel Does Not Capture

The conventional lipid panel measures total, LDL, HDL, and triglycerides. It does not measure particle number, oxidative modification, endothelial injury, vascular inflammation, thrombotic tendency, or genetic lipoprotein variants. In a postmenopausal woman with surgical menopause, a strong family history of premature coronary artery disease, and the clinical features this patient presented with, the standard panel is a starting point — not a complete assessment.

An expanded functional cardiovascular panel was ordered:

The picture that emerged was materially different from the one the standard lipid panel had suggested.

The Expanded Picture: Understanding Each Layer

ApoB of 112 mg/dL indicated a high number of atherogenic particles regardless of their size. LDL particle number — measured via ApoB — is a stronger predictor of cardiovascular events than LDL-C in multiple large prospective studies, particularly in the context of metabolic dysfunction. This patient’s LDL-C of 128 was misleading because her particles were numerous even if individually moderate in size.

Lp(a) of 142 nmol/L placed her in a high-risk category. Lp(a) is a genetically determined lipoprotein that carries both pro-atherogenic and pro-thrombotic properties via its structural homology to plasminogen. It is not modifiable through diet and responds minimally to most lipid-lowering medications at standard doses. Its elevation substantially amplifies the clinical significance of her family history and changes the aggressiveness of the entire prevention picture. For a deeper look at Lp(a) in clinical practice, see the Understanding Lp(a): The Overlooked Marker of Cardiovascular Risk article in this series.

Oxidized LDL of 74 U/L indicated that LDL particles were undergoing lipid peroxidation — a key step in the formation of foam cells and atherosclerotic plaque. Oxidized LDL is not measured on any standard panel but is a direct marker of the oxidative environment driving atherogenesis.

LP-PLA2 (PLAC test) of 228 ng/mL added a layer that hsCRP alone does not provide. Lipoprotein-associated phospholipase A2 is produced by macrophages within arterial plaques and circulates bound to LDL particles. Unlike hsCRP, which reflects systemic inflammation from multiple possible sources, LP-PLA2 is vascular-specific — it marks active inflammatory activity within the arterial wall itself. Elevated LP-PLA2 is independently associated with increased risk of coronary events and stroke and is particularly relevant in this patient given her ApoB elevation, as LP-PLA2 co-localizes with atherogenic particles. The combination of elevated LP-PLA2 with elevated oxidized LDL and hsCRP in this case painted a consistent picture: not just a high burden of particles, but particles operating in an actively inflamed, oxidized vascular environment.

MPO of 680 pmol/L indicated active endothelial injury. Myeloperoxidase is released by neutrophils and macrophages at the site of arterial wall inflammation and directly oxidizes LDL within the plaque. Elevated circulating MPO reflects ongoing oxidative damage at the endothelial level and is associated with plaque destabilization — the mechanism behind acute coronary events in patients who may not have severely stenotic lesions. In this patient, MPO provided evidence that the inflammatory process was not merely systemic but was actively occurring at the vascular wall.

ADMA of 0.72 µmol/L identified impaired nitric oxide bioavailability. Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase — the enzyme responsible for producing the nitric oxide that maintains vascular tone, inhibits platelet aggregation, and suppresses smooth muscle proliferation. When ADMA is elevated, nitric oxide production is competitively inhibited, and the vessel loses its natural anti-atherogenic regulation. ADMA elevation precedes clinically detectable atherosclerosis and is independently predictive of cardiovascular events. In this patient, it confirmed endothelial dysfunction as an active component of her cardiovascular risk — not a future possibility, but a present physiologic reality.

SDMA of 0.52 µmol/L was mildly elevated. Symmetric dimethylarginine is a structural isomer of ADMA that reflects overall methylarginine burden and has associations with renal function, endothelial integrity, and nitric oxide pathway disruption. In the context of this case — elevated homocysteine, impaired methylation capacity, and early insulin resistance — the SDMA elevation added a consistent signal of compromised vascular biochemistry rather than representing an isolated finding.

Homocysteine of 14.2 mcmol/L indicated a methylation deficit. Elevated homocysteine damages vascular endothelium through endothelial dysfunction, smooth muscle proliferation, and oxidative stress. It is independently associated with cardiovascular events and is modifiable through targeted active-form B vitamin support once the root cause is identified. For a clinical deep dive into homocysteine as a cardiovascular marker, the Homocysteine: The Underordered Cardiovascular Risk Marker article covers the mechanism and clinical response in detail.

Fasting insulin of 16 mIU/L with HOMA-IR of 2.8 confirmed insulin resistance. Surgical menopause at 51 removes the insulin-sensitizing effects of estradiol abruptly. Estrogen regulates glucose uptake in skeletal muscle, hepatic glucose production, and adipokine signaling; its loss creates a metabolic environment that accelerates insulin resistance independent of dietary behavior. This patient’s weight gain was not simply caloric — it was a metabolic consequence of abrupt estrogen withdrawal.

The Estrogen Loss Variable

This case cannot be understood without engaging the role of estrogen in cardiovascular protection. Endogenous estradiol maintains vascular tone and endothelial function via nitric oxide synthase upregulation, inhibits vascular smooth muscle proliferation, reduces LDL oxidation susceptibility, and exerts favorable effects on lipoprotein distribution — shifting the balance toward larger, less atherogenic LDL particles. Abrupt surgical menopause removes these effects simultaneously rather than gradually as in natural menopause, producing a more rapid metabolic and cardiovascular deterioration.

This patient’s estradiol was undetectable at the time of evaluation. Three years post-oophorectomy without hormone therapy, her vascular environment had been without estrogen-mediated protection for the entirety of the period in which these cardiovascular markers had been accumulating. The ADMA elevation — reflecting compromised nitric oxide bioavailability — is in part an estrogen-loss story. The favorable effect of estradiol on endothelial nitric oxide synthase (eNOS) activity is well-established; its removal directly contributes to the endothelial dysfunction pattern this patient exhibited across multiple markers.

The Homocysteine Investigation

Elevated homocysteine warranted further workup before supplementing. MTHFR genotyping revealed compound heterozygosity for C677T and A1298C variants, confirming impaired methylenetetrahydrofolate reductase activity and reduced capacity to convert folic acid to the active methylfolate form. Active B12 (holotranscobalamin) was low at 47 pmol/L, and RBC folate was at the lower limit of the functional range.

This methylation deficit had implications beyond cardiovascular risk. Compromised methylation affects Phase II estrogen detoxification — the COMT enzyme responsible for inactivating catecholestrogens requires adequate methylation capacity to function. In a patient being considered for hormone therapy, ensuring active-form B vitamin sufficiency was a prerequisite for safe estrogen metabolism, not an optional nutrient recommendation.

Physiologic Phenotyping: The Boston Heart Cholesterol Balance Test

With the biomarker picture established, the next clinical question was mechanistic: where is the cholesterol excess coming from, and why is it not being cleared? The answer shapes the intervention decisively.

The Boston Heart Cholesterol Balance test measures two sets of markers that distinguish between two distinct physiologic phenotypes:

Cholesterol synthesis markers — lathosterol and desmosterol — reflect the rate at which the liver is producing new cholesterol via the HMG-CoA reductase pathway. Elevated synthesis markers indicate the liver is overproducing cholesterol endogenously.

Cholesterol absorption markers — campesterol, sitosterol, and cholestanol — reflect the rate at which dietary and biliary cholesterol is being absorbed from the gut. Elevated absorption markers indicate the gut is retaining too much cholesterol rather than excreting it efficiently.

This patient’s results showed elevated campesterol and sitosterol with normal lathosterol — a hyperabsorber phenotype. Critically, she also showed elevated lathosterol on the synthesis side, making her a combined hyperabsorber and hypersynthesizer. This phenotype carries meaningful clinical implications for treatment selection.

Statins work by inhibiting HMG-CoA reductase — they suppress synthesis. In a pure hyperabsorber, statin monotherapy is less effective because the primary driver of elevated LDL is not synthesis but absorption. In this patient’s combined phenotype, a statin addresses the synthesis component, but without targeting the absorption side — via ezetimibe or bile acid sequestrants — the clinical response will be partial at best.

Understanding the patient’s cholesterol physiology prevented a common clinical error: reflexively initiating statin therapy and assuming the problem was addressed when LDL-C declined on paper but the underlying absorption excess remained active. The Boston Heart result also provided a framework for monitoring — repeat testing after intervention can confirm whether the target pathway is responding.

Imaging: Moving Beyond Biomarkers to Anatomy

With a biomarker profile showing elevated Lp(a), vascular-specific inflammation, active endothelial injury, ADMA-mediated nitric oxide dysfunction, and insulin resistance — alongside a strong family history of premature coronary artery disease — the clinical question shifted from risk estimation to disease presence: Was atherosclerosis already established in this patient’s coronary arteries?

A coronary CT angiography (CCTA) was ordered using the Cleerly AI platform. Cleerly’s automated quantitative plaque analysis measures total plaque volume, non-calcified plaque burden, percent atheroma volume, and plaque distribution across the coronary tree — providing a more complete picture of vascular disease than coronary artery calcium (CAC) scoring alone. CAC detects only calcified plaque; in younger women and metabolically driven presentations, significant non-calcified plaque may be present with a CAC score of zero. For a detailed review of CAC scoring, CCTA, and how to select between imaging modalities in clinical practice, see Cardiovascular Risk Screening in Functional Medicine: CIMT, CAC, and Coronary CT Angiography.

The Cleerly result showed mild levels of soft, non-calcified plaque in the proximal LAD. The CAC score was zero — a result that, without the CCTA, would have incorrectly classified this patient as low near-term risk and potentially deferred treatment.

This finding changed the clinical calculus in a fundamental way. The patient now had:

• Documented soft plaque in the proximal LAD
• Lp(a) of 142 nmol/L — a non-modifiable thrombotic risk factor associated with plaque rupture and acute coronary events
• Active vascular-wall inflammation confirmed by LP-PLA2 and MPO
• Endothelial dysfunction confirmed by ADMA
• A hyperabsorber and hypersynthesizer cholesterol phenotype
• A strong family history of premature CAD
• Three years without estrogen-mediated vascular protection

Clinical Decision-Making: The Full Picture Together

The conversation with this patient was not “your cholesterol is borderline, let’s watch it.” It was a frank discussion of a multi-pathway risk profile that, taken together, constituted meaningful active disease requiring a structured response.

The treatment plan was built to address each identified driver simultaneously rather than sequentially, given the degree of risk present:

Methylation and homocysteine. Active-form B vitamins — methylfolate, methylcobalamin, and P5P — were initiated at therapeutic doses, with a homocysteine target below 7 mcmol/L at reassessment. Methylation adequacy was also framed as a prerequisite for safe initiation of hormone therapy.

Cholesterol phenotype-targeted intervention. Given the combined hyperabsorber and hypersynthesizer pattern, a low-dose statin was initiated to address the synthesis excess, with ezetimibe added to target the absorption pathway directly. Repeat Boston Heart testing was scheduled at the six-month reassessment to evaluate phenotypic response.

Endothelial and antioxidant support. Omega-3 fatty acids at a therapeutic dose were added to support MPO-driven oxidative injury and vascular inflammation. CoQ10 and vitamin D repletion to functional sufficiency addressed the antioxidant and immune components of the endothelial dysfunction picture.

Metabolic intervention. Dietary carbohydrate modification, resistance training three days per week, and structured daily movement addressed the insulin resistance driving SHBG suppression, Lp(a) amplification, and ongoing endothelial dysfunction. Metabolic recovery was framed explicitly as cardiovascular intervention, not lifestyle advice.

Hormone therapy. Initiation of systemic estrogen therapy was recommended and accepted by the patient after a thorough shared decision-making discussion. The evidence supporting a cardioprotective window for estrogen therapy initiated within ten years of menopause onset — the timing hypothesis — is well-supported in the literature, with the ELITE trial and observational data from the Nurses’ Health Study providing the strongest evidence in this regard. For a woman who entered menopause at 51 via oophorectomy and was now 54, the window remained clinically relevant. Importantly, active-form B vitamin support and methylation adequacy were confirmed before HRT initiation, given the MTHFR compound heterozygosity and its implications for estrogen detoxification capacity. Oral progesterone was added for endometrial protection and as a favorable adjunct to the sleep and neurological symptoms the patient reported. Transdermal estradiol was chosen over oral delivery to minimize hepatic first-pass effects on lipid metabolism and coagulation factors.

Lp(a) monitoring and emerging therapeutics. Lp(a) was discussed explicitly as a genetically fixed, non-modifiable risk factor that demanded aggressive management of every other cardiovascular variable within reach. Emerging pharmacologic options targeting Lp(a) directly — including RNA-based therapeutics in late-stage clinical development — were noted as a future consideration pending trial completion and regulatory status.

Clinical Reasoning: What This Case Teaches

Standard lipid panels were designed to screen populations, not to comprehensively assess individual cardiovascular risk. The markers added in this evaluation — ApoB, Lp(a), oxidized LDL, LP-PLA2, MPO, ADMA, SDMA, hsCRP, homocysteine, and fasting insulin — are each independently predictive, each clinically actionable in different ways, and each invisible on the standard panel.

LP-PLA2 and MPO are worth particular emphasis for practitioners who are not yet routinely ordering them. hsCRP tells you there is systemic inflammation somewhere; LP-PLA2 localizes it to the arterial wall. MPO tells you the neutrophils and macrophages within the plaque are actively producing reactive oxygen species capable of oxidizing LDL in situ. In a patient with borderline conventional lipids, these two markers may be the most important signals in the entire panel.

ADMA is the endothelial physiology marker that closes the loop. A patient can have normal blood pressure, no clinical symptoms, and a CAC of zero — and still have measurably impaired endothelial function that is accumulating injury every day. ADMA makes that process visible and actionable before it becomes anatomically detectable.

The Boston Heart Cholesterol Balance test shifted the intervention from generic to precise. Without knowing the physiologic phenotype, treatment selection is a guess. A hyperabsorber treated with a statin alone is incompletely treated. A hypersynthesizer treated with ezetimibe alone misses the primary driver. Phenotyping removes the guesswork.

The imaging layer is where the clinical picture became undeniable. A CAC score of zero, taken in isolation, would have created a false sense of reassurance in a patient with mild non-calcified plaque, Lp(a) of 142, active vascular inflammation, and endothelial dysfunction. CAC measures calcified plaque. Non-calcified plaque — particularly the lipid-rich, soft plaque associated with acute coronary syndromes — is invisible to it. The Cleerly CCTA revealed what the CAC could not, and the combination of soft plaque with an inflammatory and thrombotic biomarker profile created the clinical conviction to act.

Closing

This patient was told her cholesterol was borderline and to come back in six months. She had Lp(a) of 142 nmol/L, active endothelial injury confirmed by MPO, vascular-specific inflammation confirmed by LP-PLA2, impaired nitric oxide production confirmed by ADMA, a cholesterol phenotype that would have made standard statin therapy only partially effective, and visible soft plaque in the LAD on imaging. None of that was visible on the standard lipid panel.

Functional cardiovascular medicine is not just about ordering more tests. It is about the right labs and sking the right questions — and understanding which tools answer which questions at each layer of the clinical picture.

Practitioners who want to develop a systematic approach to advanced cardiovascular risk assessment in women — including the integration of hormone status, advanced lipid phenotyping, endothelial function markers, and imaging decision-making — will find this clinical framework covered in depth within the Adapt Functional Medicine Practitioner Training and Certification Program.